Drug Profile
MGD 014
Alternative Names: MGD014Latest Information Update: 29 Aug 2022
Price :
$50
*
At a glance
- Originator MacroGenics
- Class Antiretrovirals; Bispecific antibodies; Proteins
- Mechanism of Action CD3 antigen inhibitors; Viral RNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I HIV infections; HIV-1 infections
Most Recent Events
- 24 Aug 2022 Phase-I clinical trials in HIV-1 infections (Treatment-experienced, Combination therapy) in USA (Parenteral) (NCT05261191)
- 16 Mar 2022 Phase I development is ongoing in USA
- 02 Mar 2022 MacroGenics plans a phase I trial for HIV-1 infections (Combination therapy, Treatment-experienced) in May 2022 (NCT05261191)